Skip to Content
logo

Giving patients treatment options

VIVUS is dedicated to meeting the needs and improving quality of life of patients with serious medical conditions and life-limiting diseases.

Our commercial products are indicated for the treatment of obese and overweight patients (Qsymia®) and exocrine pancreatic insufficiency (PANCREAZE®). According to the National Institutes of Health, overweight and obesity combined are the second leading cause of preventable death in the United States. Exocrine pancreatic insufficiency (EPI) affects many patient populations, including patients with cystic fibrosis, chronic pancreatitis, celiac disease, diabetes, both type 1 and type 2, inflammatory bowel disease and HIV infection.

Approved in the United States

PANCREAZE logo

PANCREAZE®

(pancrelipase) delayed-release capsules

PANCREAZE is a combination of porcine-derived lipases, proteases, and amylases indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions.

Warnings and Precautions:

PANCREAZE may increase your chance of having a serious, rare bowel disorder called fibrosing colonopathy that may require surgery. The risk of having this condition may be reduced by following the dosing instructions that your healthcare provider gave you. Take PANCREAZE exactly as prescribed by your doctor. Do not take more or less PANCREAZE than directed by your doctor.

Call your doctor right away if you have any unusual or severe stomach area (abdominal) pain, bloating, trouble passing stool (having bowel movements), nausea, vomiting, or diarrhea.

PANCREAZE Resources

Visit Pancreaze.com Download Full US Prescribing Information for PANCREAZE Download Medication Guide for PANCREAZE
View Press Release
Qsymia logo

Qsymia®

(phentermine and topiramate extended-release capsules) CIV

Qsymia is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in:

  • Adults with an initial body mass index (BMI) of:
    • 30 kg/m2 or greater (obese) or
    • 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbidity such as hypertension, type 2 diabetes mellitus, or dyslipidemia
  • Pediatric patients aged 12 years and older with an initial BMI in the 95th percentile or greater standardized for age and sex

Limitations of Use:

The effect of Qsymia on cardiovascular morbidity and mortality has not been established. The safety and effectiveness of Qsymia in combination with other products intended for weight loss, including prescription and over-the-counter drugs, and herbal preparations, have not been established.

Qsymia Resources

Visit Qsymia.com Download Full US Prescribing Information for Qsymia Download Medication Guide for Qsymia

Important Safety Information:

QSYMIA (phentermine and topiramate extended-release capsules) CIV is contraindicated in pregnancy; in patients with glaucoma; in hyperthyroidism; in patients receiving treatment or within 14 days following treatment with monoamine oxidase inhibitors; or in patients with hypersensitivity to sympathomimetic amines, topiramate, or any of the inactive ingredients in QSYMIA.

QSYMIA can cause fetal harm. It is recommended that patients who can become pregnant obtain a negative pregnancy test result before starting QSYMIA treatment, perform monthly pregnancy testing, and use effective contraception while taking QSYMIA. If a patient becomes pregnant while taking QSYMIA, treatment should be discontinued immediately, and the patient should be informed of the potential hazard to the fetus.

The most common adverse reactions reported in the pediatric clinical trial included depression, dizziness, arthralgia, pyrexia, influenza, and ligament sprain. The most common adverse reactions in adults are paraesthesia, dizziness, an altered or impaired sense of taste, insomnia, constipation, and dry mouth.

View Press Release

REMS Program

A Risk Evaluation and Mitigation Strategy (REMS) is a strategy to manage known or potential serious risks associated with a drug product and is required by the Food and Drug Administration (FDA) to ensure that the benefits of a drug outweigh its risks. The FDA has required a REMS for Qsymia. For more information visit:

www.qsymiarems.com

Other Links & Resources

Investors + Media
Relations Portal

Our Pipeline
 

Explore Careers
@ VIVUS

REMS Program
for Qsymia®

You are about to leave the VIVUS LLC website

Links to third-party websites on VIVUS.com are provided solely for your convenience.

VIVUS LLC does not control the content contained on any third-party website linked from this website. Activities on third-party websites will be governed by the policies and terms of use of those third parties.

Cancel
Continue